Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2022 Sep 19;13:991879. doi: 10.3389/fphar.2022.991879

Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

Yinchen Shen 1,2,3,4,5, Hanying Wang 1,2,3,4,5, Xiaoyin Xu 1,2,3,4,5, Chong Chen 1,2,3,4,5, Shaopin Zhu 1,2,3,4,5, Lu Cheng 1,2,3,4,5, Junwei Fang 1,2,3,4,5,*, Kun Liu 1,2,3,4,5,*, Xun Xu 1,2,3,4,5
PMCID: PMC9527301  PMID: 36199690

Graphical Abstract

AMD, age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; PLS-DA, partial least squares discriminant analysis; LPC, lysophosphatidylcholine; PC, phosphocholine; ROC, operating characteristic curve; AUC, area under the receiver operating characteristic curve; vWF, von Willebrand Factor. Note: The protein structure of vWF is downloaded from PDB (https://www.rcsb.org/).graphic file with name FPHAR_fphar-2022-991879_wc_abs.jpg

Keywords: anti-vegf, neovascular age-related macular degeneration, polypoidal choroidal vasculopathy, metabolomics, treatment response

Abstract

Background: Neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) are major causes of blindness in aged people. 30% of the patients show unsatisfactory response to anti-vascular endothelial growth factor (anti-VEGF) drugs. This study aims to investigate the relationship between serum metabolome and treatment response to anti-VEGF therapy.

Methods: A prospective longitudinal study was conducted between March 2017 and April 2019 in 13 clinical sites in China. The discovery group were enrolled from Shanghai General Hospital. The validation group consisted of patients from the other 12 sites. Participants received at least one intravitreal injection of 0.5 mg anti-VEGF drug, conbercept, and were divided into two groups - responders and non-responders. Serum samples of both groups were processed for UHPLC-MS/MS analysis. We constructed principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) models to investigate the metabolic differences between two groups using SIMCA-P. Area under curve (AUC) was calculated to screen the biomarkers to predict treatment response. Metabolites sub-classes and enriched pathways were obtained using MetaboAnalyst5.0.

Results: 219 eyes from 219 patients (nAMD = 126; PCV = 93) were enrolled. A total of 248 metabolites were detected. PCA and PLS-DA models of the discovery group demonstrated that the metabolic profiles of responders and non-responders clearly differed. Eighty-five differential metabolites were identified, including sub-classes of diacylglycerophosphocholines, lysophosphatidylcholine (LPC), fatty acids, phosphocholine, etc. Responders and non-responders differed most significantly in metabolism of LPC (p = 7.16 × 10^-19) and diacylglycerophosphocholine (p = 6.96 × 10^-17). LPC 18:0 exhibited the highest AUC, which is 0.896 with 95% confidence internal between 0.833 and 0.949, to discriminate responders. The predictive accuracy of LPC 18:0 was 72.4% in the validation group.

Conclusions: This study suggests that differential metabolites may be useful for guiding treatment options for nAMD and PCV. Metabolism of LPC and diacylglycerophosphocholine were found to affect response to conbercept treatment. LPC 18:0 was a potential biomarker to discriminate responders from non-responders.

Introduction

Neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) are major causes of blindness in people worldwide over 50 years old. More than 20% of the ageing population may suffer from the disorders (Lim et al., 2012). The Global Burden of Disease Study 2010 reported an increase of 160% in years lived with disability related to AMD (Vos et al., 2012). nAMD, characterized by the subfoveal choroidal neovascularization (CNV), have been found to cause structural damage to the macular and lead to irreversible central vision impairment or even blindness within a few years (Rastoin et al., 2020). PCV, a subtype of nAMD, however, is thought to potentially have different pathogenic mechanisms. It is mostly found in Asian population, manifested as orange-red nodular lesions (Ho et al., 2018).

The common etiology of nAMD and PCV is due to the pathological angiogenesis mediated by the vascular endothelial growth factor (VEGF) (Rastoin et al., 2020). Therefore, intravitreal anti-VEGF therapy is recommended as the first-line treatment option for this kind of disease (Campa et al., 2011; Cheung et al., 2018; Toto et al., 2021). Despite the efficacy of anti-VEGF drugs, real-world outcomes were found to be less favorable than the results of randomized-controlled clinical trials (Schmidt-Erfurth et al., 2014). Anti-VEGF drugs only delayed the progression to blindness, and about 30% of the patients show unsatisfactory response to treatment (Rastoin et al., 2020; Mettu et al., 2021). Recent studies demonstrated that the inter-individual differences in treatment response depended on a variety of factors, such as age, lifestyles, anatomical structure of the lesions, genetic polymorphism, etc (Amoaku et al., 2015). Although intravitreal injection has been proved to be safe, intraocular infection remains a severe and destructive complication (Storey et al., 2020). In the developing countries, the economic burden of multiple anti-VEGF treatments is also an unavoidable social problem.

For the reasons above, it is urgent to develop effective methods to predict response to anti-VEGF therapy and to personalize treatment options. Metabolomics studies are developed to uncover metabolic alteration in response to external or internal subtle perturbation. As metabolism is located at the end of life activities, metabolomics can reflect the changes that have occurred in the organism. Therefore, metabolomics data can be more easily correlated with clinical phenotypes. Dysregulation of lipid and metabolic pathways were found to play important roles in the development of AMD (Hou et al., 2020) and PCV (Li et al., 2016). Nevertheless, the serum lipid and metabolic differences between responders and non-responders remained unclear. We believe that there is a great need to better understand response to anti-VEGF therapy and that metabolomics is a potential area for addressing it. Therefore, the aim of this study is to conduct metabolic profiling to identify reliable serum biomarkers to discriminate responders to anti-VEGF treatment.

Materials and methods

Study design

A prospective longitudinal study was conducted between March 2017 and April 2019 in 13 clinical sites in China. The discovery group were enrolled from Department of Ophthalmology, Shanghai General Hospital, School of medicine, Shanghai Jiao Tong University, Shanghai, China, from 13 March 2017 to 1 March 2019. The last patient last visit (LPLV) of the discovery group was on 1 April 2019. The validation group consisted of patients from another 12 clinical sites in mainland China, from 28 April 2017 to 20 December 2018. The LPLV of the validation group was on 21 January 2019. Figure 1 shows the procedure of the study. This study was approved by the ethics committee of Shanghai General Hospital (permit No. 2016KY115-2), in accordance with the Declaration of Helsinki, and the other clinical sites also obtained the ethical approval. This study was registered on www.ClinicalTrial.gov (NCT03128463). All subjects provided written consent forms. The study protocol has been published (Jin et al., 2018), and here we report the metabolic analysis results.

FIGURE 1.

FIGURE 1

Open in a new tab

The procedure of the study.

Study subjects

The inclusion criteria were: (i) Age ≥50 years; (ii) Diagnosed as nAMD or PCV, and the diagnosis criteria was according to the guideline of Chinese Ocular Fundus Disease Society (The Clinical Guideline and Clinical Pathway Development Committee of Age-Related Macular Degeneration, Ocular Fundus Diseases Society, Chinese Ophthalmological Society, Chinese Medical Association, 2013); (iii) Received at least one intravitreal injection of conbercept (Lumitin; Chengdu Kanghong Biotech Co., Ltd., Chengdu, China). The exclusion criteria included: (i) Intravitreal or systemic administration of anti-VEGF drugs within 3 months; (ii) Other interventional therapies within 3 months (e.g. photodynamic therapy, retinal photocoagulation, pars plana vitrectomy, etc); (iii) Other reasons that caused subretinal of intraretinal fluid/hemorrhage, such as diabetic retinopathy, retinal venous occlusion, etc.; (iv) Serious systemic diseases, such as renal failure.

At Visit 1 (V1), all participants underwent comprehensive ophthalmologic examinations, including slit-lamp biomicroscopy, best-corrected visual acuity (BCVA) using standard Early Treatment Diabetic Retinopathy Study (ETDRS) letters, intraocular pressure (IOP) measurement, color fundus photography, and spectral-domain optical coherence tomography (SD-OCT) (Spectralis; Heidelberg Engineering, Heidelberg, Germany). All OCT scans were centered on the fovea, using a centrally oriented internal fixation mark. Central retinal thickness (CRT) within 1 mm of the central fovea were calculated automatically by the instrument. Fundus fluorescein angiography and indocyanine green angiography were also performed for the differential diagnosis of nAMD and PCV, except for the participants who had a history of allergy. The retinal specialists confirmed the diagnosis based on the fundus and morphology examinations, and then they administered intravitreal injections of 0.5 mg conbercept in the operation room under topical anesthesia. One month after treatment, a routine follow-up Visit 2 (V2) was performed. The results of BCVA, IOP, and SD-OCT were collected in V2.

Grading of the response to Anti-VEGF therapy

In the discovery group, grading of response was based on the morphology changes on SD-OCT scans from V1 to V2, such as reduction in intraretinal fluid (IRF), subretinal fluid (SRF), and retinal thickening, independently judged by two experienced graders (Yinchen Shen, Hanying Wang). The grading was confirmed by a senior retinal specialist (Xun Xu). In case of discrepancy, a final agreement was reached by all the graders. Responders were defined as patients with a significant reduction in IRF or SRF and retinal thickening. Non-responders were defined as patients with an increase or no change in IRF, SRF, and retinal thickening, from V1 to V2 (Amoaku et al., 2015). In the validation group, responders were defined as patients with a reduction of CRT ≥10% of the baseline values, while non-responders were those with a reduction of CRT <10% of the baseline values or an increase of CRT 1 month after one injection of conbercept.

Collection and pretreatment of serum samples

10 ml patients’ peripheral blood was obtained fasting in the morning before anti-VEGF injection at V1 and at V2, respectively, then was centrifuged within 30 min (1,500 rpm, 10 min at 20°C). The serum aliquots were collected and stored at −80°C immediately for further analysis. The procedures to extract metabolites were as follows: 100 μL sample was extracted by 4-fold volume methanol extraction agent. The mixture was then vortexed and centrifuged. 180 μL lyophilized samples were used for positive and negative ion analysis, respectively. Before analysis, the lyophilized samples were re-dissolved with 50 μl 25% acetonitrile, and the system was balanced with blank samples. We carried quality control (QC) to monitor the stability and repeatability of the analysis. The QC samples were prepared the same way by pooling equal volume of all serum samples, injected after every ten samples.

Metabolomics profiling

The samples were processed in the same batch for UHPLC-MS/MS analysis on a hybrid quadrupole-Orbitrap mass spectrometer (Vanquish UPLC-Q Exactive, Thermo Fisher Scientific, Rockford, IL, USA). For positive ion mode, we used Waters BEH C8 column (50 mm × 2.1 mm, 1.7 μm) (Waters, Milford, MA) to separate mixture at 60°C. Phase A: water with 0.1% formic acid; phase B: acetonitrile with 0.1% formic acid. Flow rate was set at 0.4 ml/min with the following gradient: 0–0.5 min, 5%B; 0.5–2 min, linearly increased to 40%B; 2–8 min, linearly increased to 100% B; maintained for 2 min; 10.1 min, decreased back to 5% B; balanced for 2 min. For negative ion mode, we used ACQUITY UPLC HSS T3 (50 mm × 2.1 mm, 1.8 μm) (Waters, Milford, MA) to separate mixture at 60°C. Phase A: 6.5 mm NH4HCO3 added to water; phase B: 95% methanol and 6.5 mM NH4HCO3 aqueous solution. Flow rate was set at 0.4 ml/min with the following gradient: 0–0.5 min, 2%B; 0.5–2 min, linearly increased to 40%B; 2–8 min, linearly increased to 100% B; maintained for 2 min; 10.1 min, decreased back to 2% B; balanced for 1.9 min. The acquisition setting for metabolomics data: full scan mode; capillary temperature, 300°C; sheath gas, 45; auxiliary gas, 10; mass resolution, 7e4. For positive ions: spray voltage, 3.50 kV; m/z range, 80–1,200. For negative ions: spray voltage, 3.00 kV; m/z range, 80–1,200.

Statistical analysis

The descriptive statistics were performed with SPSS software version 22.0 (SPSS Inc. Chicago, IL, United States). Continuous variables were expressed as mean (95% confidence internal). Comparisons of patients’ age, BCVA, CRT, IOP were performed using independent-samples t-tests or Mann-Whitney U. Categorical variables were expressed as number (percentage). Comparisons of patients’ gender, ethnicity, study eye, lesion type, systemic diseases, and medicine treatments were analyzed by Chi-square tests. Meanwhile, the weighted kappa for inter-observer imaging grading was calculated to verify the reliability and accuracy of the judgement. A p value <0.05 was considered statistically significant.

For metabolomics analysis, we constructed principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) models to investigate the differences of metabolic profiles between responders and non-responders using SIMCA-P version 14.0 (Umetrics AB, Umea, Sweden). Fold change (FC) and false discovery rate (FDR) were calculated to reveal the metabolites with significant differences. The metabolites with FC > 1.2 and FDR <0.01 were defined as differential metabolites. Area under the receiver operating characteristic curve (AUC) was calculated to screen the biomarkers to discriminate responders. In order to verify the potential biomarker, its optimal cut-off value of the discovery group was employed with the validation group to test the prediction accuracy. Volcano plot, venn plot, interactive pie chart of metabolites sub-classes, and bar plot of enriched pathways were drawn using MetaboAnalyst5.0 (http://www.metaboanalyst.ca/). We created a Github page and upload all related scripts and supported data. The link of the Github page is https://github.com/epang2022/Metabolomics-Study-of-Treatment-Response-to-Conbercept-of-Patients-with-Neovascular-Age-related-Macu .

Association analysis of Anti-VEGF response - Associated genetic variants with metabolites

In order to reveal possible genetic variants related to identified metabolites in this study, a public platform Lipid Genie’s Lipid Viewer (http://www.lipidgenie.com/qtlViewer.html) was used to explore genome-metabolite connections. After selecting a specific lipid species, the Logarithm-of-Odds (LOD) and the allele effect plots for mapped Quantitative Trait Loci (QTLs) were visualized in parallel to genes located within a 3 megabase pair window of QTL’s apex LOD score.

Result

In total, 219 eyes from 219 patients (nAMD, n = 126; PCV, n = 93) were enrolled. The discovery group included 132 eyes from 132 patients (nAMD, n = 62; PCV, n = 70). Another 87 independent subjects (nAMD, n = 64; PCV, n = 23) were recruited as the validation group. A total of 248 metabolites were detected by untargeted LC-MS metabolomics analysis, and the reproducibility of analysis was confirmed by QC samples. The relative standard deviations of 226 (91.1%) metabolites were less than 30%.

Study populations

The clinical characteristics are in Table 1. There were no statistical differences in age, gender, ethnicity, study eye, baseline BCVA, and baseline CRT between responders and non-responders for both populations. The weighted kappa for inter-observer imaging grading of the discovery set was 0.862 (p < 0.001). In the discovery group, the mean CRT of responders reduced significantly from 502.8 (458.8–546.8) μm to 342.9 (315.0–370.8) μm, p < 0.001. However, CRT slightly increased from 524.5 (451.2–597.8) μm to 530.3 (455.0–605.7) μm for non-responders, p = 0.348. There were also more gains in BCVA for responders. For the validation group, CRT of responders decreased from 397.5 (351.8–443.3) μm to 260.7 (233.3–288.2) μm, p < 0.001. Nevertheless, CRT increased slightly for non-responders, from 348.9 (304.0–393.7) μm to 364.7 (319.1–410.4) μm, p = 0.076. BCVA gains for responders did not reach statistical significance.

TABLE 1.

Clinical characteristics of study populations.

Discovery group Validation group
Responders (n = 89) Non-responders (n = 43) p-value Responders (n = 48) Non-responders (n = 39) p-value
Age, years, mean (CI) a 69.6 (67.8–71.4) 68.5 (66.6–70.4) 0.408 69.0 (66.6–71.4) 67.3 (65.0–69.5) 0.306
Gender, male, n (%) b 60 (67.4) 32 (74.4) 0.412 33 (68.8) 26 (66.7) 0.836
Ethnicity, Han, n (%) b 89 (100.0) 41 (95.3) 0.103 48 (100.0) 39 (100.0) 1.000
Study eye, right, n (%) b 53 (59.6) 24 (55.8) 0.683 22 (45.8) 20 (51.3) 0.613
Lesion type, AMD, n (%) b 40 (44.9) 22 (51.2) 0.502 38 (79.2) 26 (66.7) 0.189
Clinical characteristics
 BCVA before treatment, ETDRS letters, (CI) a 39.0 (34.1–43.9) 42.2 (35.4–49.0) 0.462 41.9 (35.6–48.3) 43.8 (35.7–51.9) 0.710
 BCVA after treatment, ETDRS letters, (CI) c 46.3 (41.5–51.2) 44.4 (37.0–51.7) 0.638 48.7 (42.6–54.9) 49.0 (41.7–56.3) 0.980
 Change of BCVA, ETDRS letters, (CI) c 7.3 (4.7–10.0) 2.2 (-0.5–4.9) 0.008 6.8 (2.8–10.9) 5.2 (0.84–9.6) 0.484
 IOP before treatment, mmHg, (CI) 14.64 (13.95–15.34) 15.21 (14.31–16.11) 0.236c 13.88 (12.90–14.86) 14.62 (13.52–15.72) 0.312a
 IOP after treatment, mmHg, (CI) c 13.93 (13.35–14.51) 13.95 (13.18–14.73) 0.965 12.95 (11.98–13.91) 14.32 (13.28–15.36) 0.047
 Change of IOP, mmHg, (CI) -0.71 (-1.34∼-0.09) -1.26 (-1.86∼-0.65) 0.082c -0.93 (-1.66∼-0.20) -0.30 (-1.11–0.51) 0.245a
 CRT before treatment, μm, (CI) c 502.8 (458.8–546.8) 524.5 (451.2–597.8) 0.928 397.5 (351.8–443.3) 348.9 (304.0–393.7) 0.069
 CRT after treatment, μm, (CI) c 342.9 (315.0–370.8) 530.3 (455.0–605.7) <0.001 260.7 (233.3–288.2) 364.7 (319.1–410.4) <0.001
 Change of CRT, μm, (CI) c -159.9 (-187.1∼-132.7) 5.9 (-5.8–17.5) <0.001 -136.8 (-167.0∼-106.7) 15.9 (-1.7–33.5) <0.001
Systemic diseases at baseline, n (%) b
 Hypertension 29 (32.6) 18 (41.9) 0.297 13 (27.1) 13 (33.3) 0.527
 Diabetes 14 (15.7) 3 (7.0) 0.259 8 (16.7) 3 (7.7) 0.353
 Dyslipidemia 5 (5.6) 3 (7.0) 1.000 0 (0.0) 2 (5.1) 0.198
 Cardiac/cerebrovascular diseases 11 (12.4) 3 (7.0) 0.522 0 (0.0) 2 (5.1) 0.198
Treatments, n (%) b
 Antihypertensives 24 (27.0) 15 (34.9) 0.350 8 (16.7) 14 (35.9) 0.040
 Antihyperglycemics 12 (13.5) 2 (4.7) 0.214 6 (12.5) 1 (2.6) 0.194
 Antihyperlipidemics 3 (3.4) 4 (9.3) 0.312 1 (2.1) 0 (0.0) 1.000
Open in a new tab

BCVA, best corrected visual acuity; ETDRS, early treatment diabetic retinopathy study; IOP, intraocular pressure; CRT, central retinal thickness.

a

: Independent-samples t test.

b

: Chi-square test.

c

: Mann-Whitney U test.

Comparison of metabolic profiles before and after Anti-VEGF treatment

Both PCA and PLS-DA models were constructed for serum metabolic profiles of patients with nAMD before and after treatment. Neither model showed significant differences. The permutation test indicated that PLS-DA model of nAMD overfitted. Meanwhile, PCA model was constructed for patients with PCV before and after treatment, indicating no difference. PLS-DA model of PCV could not be established because of insignificant difference (Figure 2).

FIGURE 2.

FIGURE 2

Open in a new tab

Comparison of metabolic profiles before and after anti-VEGF treatment. (A) Principal component analysis (PCA) model of patients with nAMD before and after anti-VEGF treatment. The PCA model showed no difference. (B) Partial least squares discriminant analysis (PLS-DA) model of patients with nAMD before and after anti-VEGF treatment. The PLS-DA model also showed no difference. (C) The permutation test indicated that PLS-DA model of nAMD overfitted. (D) PCA model of patients with PCV before and after anti-VEGF treatment. The PCA model showed no difference.

Metabolic differences between responders and non-responders to Anti-VEGF treatment

For the discovery group, PCA and PLS-DA models both demonstrated that the baseline metabolic profile of responders and that of non-responders showed significant differences combining nAMD and PCV (Figure 3). In all, eighty-five differential metabolites were identified (see Supplementary Table S1). Table 2 lists the top 20 metabolites ranked by AUC. In addition, PCA and PLS-DA models were established for patients with nAMD and PCV, respectively. We also identified a clear separation between responders and non-responders in these models (Figure 4).

FIGURE 3.

FIGURE 3

Open in a new tab

Metabolic differences between responders and non-responders to anti-VEGF treatment combining nAMD and PCV. (A) Principal component analysis (PCA) model showed significant difference. (B) Partial least squares discriminant analysis (PLS-DA) model showed significant difference. (C) The permutation test demonstrated that PLS-DA model did not overfit. (D) Volcano plot of the differential metabolites between responders and non-responders. Blue and red dots indicated down-regulated and up-regulated metabolites, respectively. (E) Venn plot of the differential metabolites between responders and non-responders in AMD (30 metabolites) and the differential metabolites between responders and non-responders in PCV (47 metabolites).

TABLE 2.

Top 20 differential metabolites between responders and non-responders ranked by the area under the receiver operating characteristic curve (AUC).

No. Differential metabolites AUC FDR Log2 FC
1 LPC 18:0 sn-1 0.896 2.650 × 10^-18 0.451
2 LPC 16:0 sn-1 0.892 5.321 × 10^-17 0.449
3 LPC 16:0 sn-2 0.876 8.154 × 10^-16 0.454
4 PC 38:6 0.832 1.706 × 10^-12 0.465
5 SM 34:1 0.829 4.252 × 10^-12 0.383
6 LPC 18:1 sn-1 0.827 3.679 × 10^-11 0.323
7 PC 34:0 0.819 4.700 × 10^-11 0.380
8 PC 34:1 0.813 1.561 × 10^-10 0.415
9 PC 38:5 0.798 3.192 × 10^-8 0.477
10 PC 36:3 0.795 4.843 × 10^-9 0.363
11 PC O-38:6 0.785 4.852 × 10^-8 0.414
12 PC 36:2 0.784 5.403 × 10^-9 0.482
13 LPE 22:6 sn-1 0.784 1.147 × 10^-8 0.525
14 PC O-38:5 0.780 6.600 × 10^-8 0.357
15 LPC 18:2 sn-1 0.779 5.813 × 10^-8 0.390
16 PE O-38:7 0.778 2.551 × 10^-8 0.589
17 PC O-36:5 0.777 4.371 × 10^-8 0.426
18 LPC O-16:1 0.772 3.866 × 10^-9 0.382
19 PC 38:4 0.770 3.016 × 10^-7 0.466
20 LPC 16:1 sn-1 0.767 1.701 × 10^-8 0.459
Open in a new tab

AUC, area under the receiver operating characteristic curve; FDR, false discovery rate; FC, fold change.

FIGURE 4.

FIGURE 4

Open in a new tab

Metabolic differences between responders and non-responders to anti-VEGF treatment in nAMD and PCV, respectively. (A) Principal component analysis (PCA) model showed significant difference in nAMD. (B) Partial least squares discriminant analysis (PLS-DA) model showed significant difference in nAMD. (C) PCA model showed significant difference in PCV. (D) PLS-DA model showed significant difference in PCV.

Enriched metabolite pathways and potential biomarker associated with different response to Anti-VEGF treatment

The sub-classes of differential metabolites associated with treatment response included diacylglycerophosphocholines, lysophosphatidylcholine (LPC), branched fatty acids, unsaturated fatty acids, phosphocholine (PC), etc (Figure 5A). Responders and non-responders differed most significantly in metabolism of LPC (p = 7.16 x 10^-19) and diacylglycerophosphocholine (p = 6.96 x 10^-17). The enriched metabolites pathways are listed in Figure 5B, and the detailed information of the pathways is summarized in Supplementary Table S2. Among the differential metabolites, LPC 18:0 exhibited the highest AUC, which is 0.896 with 95% confidence internal between 0.833 and 0.949, to discriminate responders from non-responders (Figure 5C). Prediction accuracies by LPC 18:0 in the discovery and validation groups are illustrated in Figure 5D. The optimal cut-off value of LPC 18:0 in the discovery group was 11.4. This cut-off value was then used to predict treatment response in the validation group, and the predictive value was 72.4%. According to our genome-metabolite connections analysis on the platform Lipid Genie’s Lipid Viewer, the single nucleotide polymorphism (SNP) of von Willebrand Factor (vWF) was highly relevant with the level of LPC 18:0 (Figure 5E).

FIGURE 5.

FIGURE 5

Open in a new tab

Enriched metabolite pathways and potential biomarker associated with different response to anti-VEGF treatment. (A) Interactive pie chart of sub-classes of differential metabolites. (B) Bar plot of enriched metabolite pathways. Responders and non-responders differed most significantly in metabolism of LPC (p = 7.16 x 10^-19) and diacylglycerophosphocholine (p = 6.96 x 10^-17). (C) Diagnostic outcome of LPC 18:0 in the discovery group. The area under curve is 0.896 with 95% confidence internal between 0.833 and 0.949, to discriminate responders from non-responders. The optimal cut-off value of LPC 18:0 was 11.4. (D) Prediction accuracies by LPC 18:0 in the discovery and validation group. This cut-off value 11.4 was used to predict treatment response in the validation group. The predictive value was 72.4%. (E) Hotspot mapping to chromosome 6: 125.554 Mbp indicated the gene associated with LPC 18:0 (highlighted in red). The single nucleotide polymorphism of von Willebrand Factor was highly relevant with the level of LPC 18:0.

Discussion

Anti-VEGF drugs have revolutionized the treatment of retinal neovascular diseases. Conbercept, an anti-VEGF agent developed recently in China, reduced CRT in patients with nAMD in previous clinical studies (Zhang et al., 2011; Li et al., 2014; Liu et al., 2019). Nevertheless, there was still a lack of reliable and accurate methods to predict the efficacy of anti-VEGF treatment. The authors have conducted a prospective longitudinal study (NCT03128463) to investigate metabolic biomarkers related to treatment response to conbercept. The main findings of this study included three aspects.

Firstly, there were no significant differences in serum metabolic profiles before and after intravitreal injection of conbercept. Previous studies revealed that plasma level of VEGF was reduced after injection of aflibercept, but no change was found after ranibizumab treatment in patients with AMD (Wang et al., 2014; Yoshida et al., 2014; Zehetner et al., 2015). However, the influence of anti-VEGF treatment on serum metabolomics has not been reported previously. To our knowledge, our study was the first to disclose that intraocular anti-VEGF administration had little influence on serum metabolism. The diversity of treatment response was not due to the metabolic changes caused by the drug.

Secondly, the authors identified a clear difference of baseline metabolic profiles between responders and non-responders, and inferred that metabolism was one of the factors determining treatment response. Although some metabolic pathways related to the onset and progression of AMD and PCV have been studied these years, there is still no consensus over the effect of metabolomics on treatment response. The well-recognized pathways associated with AMD progression included dysregulation of lipid metabolism, nucleotide metabolism, carbohydrate metabolism, amino acid metabolism, etc (Hou et al., 2020). Interestingly, the differential metabolites we identified were mostly enriched to lipids, including lipids from subclasses of LPC, PC, carnitine, fatty acids, etc. Research on the relationship between lipids and angiogenesis was just beginning. Kananen et al. reported that high level of serum total cholesterol led to the development of AMD (Kananen et al., 2021). Samson et al. utilized chorioallantoic membrane assay of chick embryo and gas chromatography-mass spectrometry analysis to uncover the specific lipids related to angiogenesis. High levels of LPC, lysophosphatidylethanolamine and cholesterol were detected in the vessel area (Samson et al., 2021). We speculated that specific lipids might regulate the retino-choroidal angiogenesis microenvironment, resolve the activity of CNV, and therefore affect anti-VEGF response. Gao et al. implicated that the serum levels of glycerophosphocholine, LysoPC (18:2) and PS (18:0/20:4) were increased in non-responders (Gao et al., 2020), which was consistent with ours.

The most important disorder pathway we identified was LPC metabolism. In a study of patients at different stages of AMD, patients with nAMD demonstrated increased serum levels of total LPC and LPC 18:0, indicating that LPC participated in angiogenesis (Semba et al., 2019). Fundamental experiment showed that LPC was related to endothelial dysfunction via activation of PKC signaling pathway (Zhao et al., 2021). We performed ROC curve analysis to screen potential biomarkers to discriminate responders. LPC18:0 showed the highest diagnostic efficiency to predict treatment response to conbercept at the beginning of the primary phase, but the mechanism needs further research.

Apart from LPC, pathway enrichment analysis also suggested alterations of diacylglycerophosphocholine metabolism, and the principle metabolites of this pathway were PCs. Increased circulating oxidized phospholipids were related to the pathogenesis of various diseases (Karki et al., 2020). The function of PCs in eye diseases was deemed to reflect oxidative stress of lipids (Cabrerizo et al., 2017a; Cabrerizo et al., 2017b). PCs were identified as discriminating metabolites of AMD (Kersten et al., 2019) and PCV (Li et al., 2016), and our results suggested that PCs could be biomarkers to predict treatment response. Another important metabolite identified was carnitine C 14:3, and the accumulation of carnitine might have resulted from disorders of carnitine metabolism (Knottnerus et al., 2018). The major function of carnitine was to shuttle long-chain fatty acids into mitochondrial matrix (Almannai et al., 2019). Recent research revealed that the carnitine shuttle pathway was more significantly changed in nAMD than intermediate AMD (Mitchell et al., 2021), implying its role in CNV generation.

Thirdly, the authors identified genetic variants associated with differential metabolite through public data analysis, with the purpose of clarifying genome-metabolite connections. SNP of vWF was closely associated with LPC 18:0. Despite the main function of regulating bleeding disorder, vWF was one of the specific surface markers of endothelial cells (Lagarkova et al., 2008). Immunohistochemistry of CNV membranes and polypoidal vessels of human eyes verified that vWF was expressed in the vascular endothelial cells (Wakusawa et al., 2008). Yamashita et al. reported elevated plasma levels of vWF:Antigen in patients with AMD, elucidating the participation of vWF in AMD (Yamashita et al., 2018). Nevertheless, how vWF regulates LPC 18:0 needs further investigation.

Honestly, there are some limitations to this study. (i) The relative small sample size of the study population, which could influence repeatability of the results. Hence, the authors recruited 87 independent subjects from other 12 clinical sites as the validation group to verify the main findings. (ii) According to the protocol of the study, only patients receiving conbercept treatment were enrolled, which could lead to bias. Therefore, the results should be objectively interpreted, and further research is required to elucidate whether our results can be expanded to other anti-VEGF drugs. (iii) The time point to define treatment response was 1 month after the first injection. Although ‘3 + PRN’ regimen was recommended for nAMD based on the results of randomized controlled clinical trials, many patients could not afford three loading doses. Thus, it is critical to develop metabolic biomarkers to predict response at the beginning of the treatment. More longitudinal studies are needed to clarify the relationship between metabolites and response to anti-VEGF treatment in the primary phase as well as in the maintained phase.

Conclusion

Responders and non-responders treated with conbercept differed most significantly in metabolism of LPC and diacylglycerophosphocholine. LPC 18:0 could be a potential biomarker to discriminate responders. Further research is needed to confirm the relationship between lipids and angiogenesis.

Acknowledgments

The authors thank the doctors from Xijing Hospital, Air Force Medical University, Xi’an, China; Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China; Eye and ENT Hospital of Fudan University, Shanghai, China; Eye Hospital and School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, China; Shanghai 10th People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai, China; Zhongshan Hospital, Fudan University, Shanghai, China; The First Affiliated Hospital of Guangxi Medical University, Nanning, China; Wuhan General Hospital of Guangzhou Military Region, Wuhan, China; The Affiliated Eye Hospital of Nanjing Medical University, Nanjing, China; Ningbo Eye Hospital, Ningbo, China; Inner Mongolia Chaoju Eye Hospital, Hohhot, China; Ningbo First Hospital, Ningbo, China for their help during the study.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the ethics committee of Shanghai General Hospital, School of medicine, Shanghai Jiao Tong University, Shanghai, China (permit No. 2016KY115-2). The patients/participants provided their written informed consent to participate in this study.

Author contributions

YS, JF, and KL conceived and designed the study and drafted the manuscript. HW, XiX, CC, SZ, LC, and XuX provided analytical technical support. All authors have read and approved the final manuscript.

Funding

This work was funded by the National Natural Science Foundation of China (No. 8217040425, 81870667, 81800831, 82101141), National Key R&D Program of China (No. 2016YFC0904800, 2019YFC0840607), Program of Shanghai Academic Research Leader (21XD1402700), Bethune•Lumitin Young and Middle-aged Ophthalmic Research Fund (No. BJ-LM2021010J), and Science and Technology Research Project of Songjiang District (No. 2020SJ307). The sponsor or funding organization had no role in the design or conduct of this research.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.991879/full#supplementary-material

Click here for additional data file. (10.4KB, XLSX)
Click here for additional data file. (14.2KB, XLSX)

References

  1. Almannai M., Alfadhel M., El-Hattab A. W. (2019). Carnitine inborn errors of metabolism. Molecules 24, 3251. 10.3390/molecules24183251 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Amoaku W. M., Chakravarthy U., Gale R., Gavin M., Ghanchi F., Gibson J., et al. (2015). Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond.) 29, 721–731. 10.1038/eye.2015.48 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cabrerizo J., Urcola J. A., Vecino E. (2017b). Changes in the lipidomic profile of aqueous humor in open-angle glaucoma. J. Glaucoma 26, 349–355. 10.1097/IJG.0000000000000603 [DOI] [PubMed] [Google Scholar]
  4. Cabrerizo J., Urcola J. A., Vecino E., Melles G. (2017a). Changes in lipidomic profile of aqueous humour in Fuchs endothelial dystrophy. Acta Ophthalmol. 95, 727–732. 10.1111/aos.13374 [DOI] [PubMed] [Google Scholar]
  5. Campa C., Harding S. P. (2011). Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr. Drug Targets 12, 173–181. 10.2174/138945011794182674 [DOI] [PubMed] [Google Scholar]
  6. Cheung C., Lai T., Ruamviboonsuk P., Chen S. J., Chen Y., Freund K. B., et al. (2018). Polypoidal choroidal vasculopathy: Definition, pathogenesis, diagnosis, and management. Ophthalmology 125, 708–724. 10.1016/j.ophtha.2017.11.019 [DOI] [PubMed] [Google Scholar]
  7. Gao Y., Teo Y., Beuerman R. W., Wong T. Y., Zhou L., Cheung C. (2020). A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy. Sci. Rep. 10, 1341. 10.1038/s41598-020-58346-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ho C., Lai T. (2018). Current management strategy of polypoidal choroidal vasculopathy. Indian J. Ophthalmol. 66, 1727–1735. 10.4103/ijo.IJO_975_18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hou X. W., Wang Y., Pan C. W. (2020). Metabolomics in age-related macular degeneration: A systematic review. Invest. Ophthalmol. Vis. Sci. 61, 13. 10.1167/iovs.61.14.13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jin J., Shen Y., Chen X., Wang J., Chen C., Xu X., et al. (2018). Pharmacogenomic study on anti-VEGF medicine in treatment of macular neovascular diseases: A study protocol for a prospective observational study. BMC Ophthalmol. 18, 181. 10.1186/s12886-018-0812-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kananen F., Strandberg T., Loukovaara S., Immonen I. (2021). Early middle age cholesterol levels and the association with age-related macular degeneration. Acta Ophthalmol. 99, e1063–e1069. 10.1111/aos.14774 [DOI] [PubMed] [Google Scholar]
  12. Karki P., Birukov K. G. (2020). Oxidized phospholipids in healthy and diseased lung endothelium. Cells 9, 981. 10.3390/cells9040981 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kersten E., Dammeier S., Ajana S., Groenewoud J., Codrea M., Klose F., et al. (2019). Metabolomics in serum of patients with non-advanced age-related macular degeneration reveals aberrations in the glutamine pathway. PloS one 14, e0218457 10.1371/journal.pone.0218457 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Knottnerus S., Bleeker J. C., Wüst R., Ferdinandusse S., IJlst L., Wijburg F. A., et al. (2018). Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev. Endocr. Metab. Disord. 19, 93–106. 10.1007/s11154-018-9448-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lagarkova M. A., Volchkov P. Y., Philonenko E. S., Kiselev S. L. (2008). Efficient differentiation of hESCs into endothelial cells in vitro is secured by epigenetic changes. Cell cycle 7, 2929–2935. 10.4161/cc.7.18.6700 [DOI] [PubMed] [Google Scholar]
  16. Li M., Zhang X., Liao N., Ye B., Peng Y., Ji Y., et al. (2016). Analysis of the serum lipid profile in polypoidal choroidal vasculopathy. Sci. Rep. 6, 38342 10.1038/srep38342 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Li X., Xu G., Wang Y., Xu X., Liu X., Tang S., et al. (2014). Safety and efficacy of conbercept in neovascular age-related macular degeneration: Results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 121, 1740–1747. 10.1016/j.ophtha.2014.03.026 [DOI] [PubMed] [Google Scholar]
  18. Lim L. S., Mitchell P., Seddon J. M., Holz F. G., Wong T. Y. (2012). Age-related macular degeneration. Lancet 379, 1728–1738. 10.1016/S0140-6736(12)60282-7 [DOI] [PubMed] [Google Scholar]
  19. Liu K., Song Y., Xu G., Ye J., Wu Z., Liu X., et al. (2019). Conbercept for treatment of neovascular age-related macular degeneration: Results of the randomized phase 3 PHOENIX study. Am. J. Ophthalmol. 197, 156–167. 10.1016/j.ajo.2018.08.026 [DOI] [PubMed] [Google Scholar]
  20. Mettu P. S., Allingham M. J., Cousins S. W. (2021). Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog. Retin. Eye Res. 82, 100906 10.1016/j.preteyeres.2020.100906 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mitchell S. L., Ma C., Scott W. K., Agarwal A., Pericak-Vance M. A., Haines J. L., et al. (2021). Plasma metabolomics of intermediate and neovascular age-related macular degeneration patients. Cells 10, 3141. 10.3390/cells10113141 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rastoin O., Pagès G., Dufies M. (2020). Experimental models in neovascular age related macular degeneration. Int. J. Mol. Sci. 21, 4627. 10.3390/ijms21134627 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Samson F. P., Fabunmi T. E., Patrick A. T., Jee D., Gutsaeva D. R., Jahng W. J. (2021). Fatty acid composition and stoichiometry determine the angiogenesis microenvironment. ACS omega 6, 5953–5961. 10.1021/acsomega.1c00196 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schmidt-Erfurth U., Chong V., Loewenstein A., Larsen M., Souied E., Schlingemann R., et al. (2014). Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br. J. Ophthalmol. 98, 1144–1167. 10.1136/bjophthalmol-2014-305702 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Semba R. D., Moaddel R., Cotch M. F., Jonasson F., Eiriksdottir G., Harris T. B., et al. (2019). Serum lipids in adults with late age-related macular degeneration: A case-control study. Lipids Health Dis. 18, 7. 10.1186/s12944-018-0954-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Storey P. P., Patel D., Garg S. (2020). Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents. Can. J. Ophthalmol. 55, 286–292. 10.1016/j.jcjo.2020.01.015 [DOI] [PubMed] [Google Scholar]
  27. The Clinical Guideline and Clinical Pathway Development Committee of Age-Related Macular Degeneration (2013). Ocular fundus diseases society, Chinese ophthalmological society, Chinese medical AssociationClinical pathway of age-related macular degeneration in China. Chin. J. Ocul. Fundus Dis. 29, 343–355. 10.3760/cma.j.issn.1005-1015.2013.04.002 [DOI] [Google Scholar]
  28. Toto L., Di Antonio L., Costantino O., Mastropasqua R. (2021). Anti-VEGF therapy in myopic CNV. Curr. Drug Targets 22, 1054–1063. 10.2174/1389450122999210128180725 [DOI] [PubMed] [Google Scholar]
  29. Vos T., Flaxman A. D., Naghavi M., Lozano R., Michaud C., Ezzati M., et al. (2012). Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the global burden of disease study 2010. Lancet 380, 2163–2196. 10.1016/S0140-6736(12)61729-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wakusawa R., Abe T., Sato H., Yoshida M., Kunikata H., Sato Y., et al. (2008). Expression of vasohibin, an antiangiogenic factor, in human choroidal neovascular membranes. Am. J. Ophthalmol. 146, 235–243. 10.1016/j.ajo.2008.03.019 [DOI] [PubMed] [Google Scholar]
  31. Wang X., Sawada T., Sawada O., Saishin Y., Liu P., Ohji M. (2014). Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am. J. Ophthalmol. 158, 738–744. 10.1016/j.ajo.2014.06.009 [DOI] [PubMed] [Google Scholar]
  32. Yamashita M., Matsumoto M., Hayakawa M., Sakai K., Fujimura Y., Ogata N. (2018). Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration. Sci. Rep. 8, 1491. 10.1038/s41598-018-19473-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Yoshida I., Shiba T., Taniguchi H., Takahashi M., Murano T., Hiruta N., et al. (2014). Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 252, 1483–1489. 10.1007/s00417-014-2717-0 [DOI] [PubMed] [Google Scholar]
  34. Zehetner C., Kralinger M. T., Modi Y. S., Waltl I., Ulmer H., Kirchmair R., et al. (2015). Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: A randomised, prospective trial. Acta Ophthalmol. 93, e154–e159. 10.1111/aos.12604 [DOI] [PubMed] [Google Scholar]
  35. Zhang M., Zhang J., Yan M., Luo D., Zhu W., Kaiser P. K., et al. (2011). A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 118, 672–678. 10.1016/j.ophtha.2010.08.008 [DOI] [PubMed] [Google Scholar]
  36. Zhao H., He Y. (2021). The inhibitory effect of lysophosphatidylcholine on proangiogenesis of human CD34+ cells derived endothelial progenitor cells. Front. Mol. Biosci. 8, 682367 10.3389/fmolb.2021.682367 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (10.4KB, XLSX)
Click here for additional data file. (14.2KB, XLSX)

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES